APPROVAL OF PRODUCT Sample Clauses

APPROVAL OF PRODUCT. A. Each product to be approved under this Agreement shall be approved by the Contract Manager. The DSH’s determination as to satisfactory work shall be final, absent fraud or mistake.
Sample 1Sample 2Sample 3See All (9)
AutoNDA by SimpleDocs
APPROVAL OF PRODUCT. Each product to be approved under this Agreement shall be approved by the Contract Manager. HCD’s determination as to satisfactory work shall be final absent fraud, mistake or arbitrariness.
Sample 1Sample 2Sample 3See All (8)
APPROVAL OF PRODUCT. A. Each service to be approved under this Emergency Agreement shall be approved by the DSH Contract Manager. DSH’s determination as to satisfactory work shall be final, absent fraud or mistake.
Sample 1Sample 2
APPROVAL OF PRODUCT. 3.2.1 When a cGMP Batch ordered by GAMIDA has been completed, LONZA will notify GAMIDA and supply GAMIDA with the required Project Documentation set forth in this Agreement. Within [*] after GAMIDA’s receipt of such documentation regarding such cGMP Batch (the “Acceptance Period”), GAMIDA shall determine by review of such documentation whether or not the given cGMP Batch conforms to the product warranties set forth in Section 3.1 above (“Product Warranties”). If GAMIDA asserts that the cGMP Batch does not comply with the Product Warranties set forth in Section 3.1 above, GAMIDA will deliver to LONZA, in accordance with the notice provisions set forth in Section 14.4 hereof, written notice of disapproval (the “Disapproval Notice”) of such cGMP Batch, stating in reasonable detail the basis for such assertion of non-compliance with the Product Warranties. If a valid Disapproval Notice is received by LONZA during the Acceptance Period, then LONZA and GAMIDA will provide one another with all related paperwork and records (including, but not limited to, quality control tests) relating to both the production of the cGMP Batch and the Disapproval Notice. If a valid Disapproval Notice is not received during the Acceptance Period, the cGMP Batch will be deemed accepted and ready for shipment to GAMIDA, or storage for GAMIDA, as applicable. The above procedure shall not derogate from LONZA’s liability for a period of time of 60 days after delivery of the Product for any failure to comply with the Product Warranties which could not reasonably have been determined by GAMIDA from the review of the Project Documentation.
Sample 1
APPROVAL OF PRODUCT. The Artist requires that three (3) Samples of each Licensed Article will be provided to her at no cost and that the Licensed Articles will not be made commercially available until her approval is given in writing. The Client requires that the Artist give approval or disapproval within fifteen (15) days of receipt of the Samples.
Sample 1
APPROVAL OF PRODUCT. The Client shall have a period of three (3) months from receipt of the latest of the Product or the Final Report in which to notify BioReliance in writing of any failure of the Product to meet the agreed specification as detailed in the Specifications. In the event that no written notification is received within the said three (3) month period, the Client shall be deemed to have accepted the Product as meeting specification In the event of BioReliance’s receipt of a notice. In the event of BioReliance receives notice from the Client for non- conformance of Product, the Client shall make available to BioReliance the failed Product for inspection at the Facility and neither BioReliance nor the Client shall take any steps to manipulate or otherwise interfere with the Product until a final resolution is mutually agreed upon in good faith. In the event of a dispute arising as to whether the Product has failed to meet the agreed specification or as to whether any failure to meet the agreed specification is as a result of any act or omission of the Client or any party acting on behalf of the Client or with the authority of the Client or any third party following upon delivery of the Product to the Client, the dispute shall be referred to an independent expert. The independent expert (acting as an expert and not an arbiter) shall be appointed by agreement between BioReliance and the Client or in the absence of agreement within a period of twenty (20) days of the request for referral having been notified by either BioReliance or the Client to the other party. The decision of the expert on the matter under referral, including the award of expenses, shall be final and binding on the parties in the absence of manifest error. Should it be a condition of the contract, or should the Client request and BioReliance consent to the Product being released to the Client prior to the completion of the Quality Assurance Audit or prior to the completion of any tests (including mycoplasma and sterility) forming part of the Production Services or services relating thereto and release of the results thereof, the Client warrants that the Product shall not be used by it, prior to such completion and release of results, for the purposes of clinical trials and the Client further acknowledges that any use of the Product prior to acceptance by it shall be at the Client’s risk, and in respect of any such use of the Product prior to such acceptance the Client undertakes to indemnify BioReli...
Sample 1

Related to APPROVAL OF PRODUCT

  • Regulatory Approval 25.1 The Parties understand and agree that this Agreement and any amendment or modification hereto will be filed with the Commission for approval in accordance with Section 252 of the Act and may thereafter be filed with the FCC. The Parties believe in good faith and agree that the services to be provided under this Agreement are in the public interest. Each Party covenants and agrees to fully support approval of this Agreement by the Commission or the FCC under Section 252 of the Act without modification.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • No Regulatory Approval By the Company or Parent, if its Board of Directors so determines by a vote of a majority of the members of its entire Board, in the event any Requisite Regulatory Approval shall have been denied by final, nonappealable action by such Governmental Authority or a Governmental Authority shall have requested the permanent withdrawal of an application therefor.

  • Regulatory Approvals; Efforts (a) Prior to the Closing, Parent, Merger Sub and the Company shall use their respective reasonable best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all things necessary, proper or advisable under any applicable Laws to consummate and make effective the Merger including (i) the preparation and filing of all forms, registrations and notices required to be filed to consummate the Merger, (ii) the satisfaction of the conditions to consummating the Merger, (iii) taking all reasonable actions necessary to obtain (and cooperating with each other in obtaining) any consent, authorization, Order or approval of, or any exemption by, any third party, including any Governmental Entity (which actions shall include furnishing all information and documentary material required under the HSR Act) required to be obtained or made by Parent, Merger Sub, the Company or any of their respective Subsidiaries in connection with the Merger or the taking of any action contemplated by this Agreement, and (iv) the execution and delivery of any additional instruments necessary to consummate the Merger and to fully carry out the purposes of this Agreement. Additionally, each of Parent, Merger Sub and the Company shall use reasonable best efforts to fulfill all conditions precedent to the Merger and shall not take any action after the date of this Agreement that would reasonably be expected to materially delay the obtaining of, or result in not obtaining, any permission, approval or consent from any such Governmental Entity necessary to be obtained prior to Closing. To the extent that transfers of any permits issued by any Governmental Entity are required as a result of the execution of this Agreement or the consummation of the Merger, the parties hereto shall use reasonable best efforts to effect such transfers.

  • Licensed Territory Worldwide NIH Patent License Agreement—Exclusive APPENDIX C – ROYALTIES Royalties:

  • Other Regulatory Approvals Each party hereto shall cooperate and use its reasonable best efforts to promptly prepare and file all necessary documentation to effect all necessary applications, notices, petitions, filings and other documents, and use all reasonable efforts to obtain (and will cooperate with each other in obtaining) any consent, acquiescence, authorization, order or approval of, or any exemption or nonopposition by, any Governmental Entity required to be obtained or made by Parent or the Company or any of their respective Subsidiaries in connection with the Offer and the Merger or the taking of any other action contemplated by this Agreement.

  • Cooperation with Regulatory Authorities The parties to this Agreement each agree to cooperate in a reasonable manner with each other in the event that any of them should become involved in a legal, administrative, judicial or regulatory action, claim, or suit as a result of performing its obligations under this Agreement.

  • Regulatory Approvals All Requisite Regulatory Approvals shall have been obtained and shall remain in full force and effect and all statutory waiting periods in respect thereof shall have expired, and no such Requisite Regulatory Approval shall have resulted in the imposition of any Materially Burdensome Regulatory Condition.

Time is Money Join Law Insider Premium to draft better contracts faster.